TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 138 filers reported holding TRAVERE THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 0.71 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,497,861 | +43.4% | 167,546 | +146.4% | 0.00% | – |
| Q2 2023 | $1,044,265 | -80.8% | 67,986 | -71.8% | 0.00% | -100.0% |
| Q1 2023 | $5,425,578 | +700.2% | 241,244 | +761.8% | 0.00% | – |
| Q2 2022 | $678,000 | -48.3% | 27,994 | -45.0% | 0.00% | – |
| Q1 2022 | $1,312,000 | +9.2% | 50,900 | +31.5% | 0.00% | – |
| Q4 2021 | $1,202,000 | +375.1% | 38,704 | +271.5% | 0.00% | – |
| Q3 2021 | $253,000 | -79.0% | 10,418 | -87.4% | 0.00% | – |
| Q2 2021 | $1,207,000 | +402.9% | 82,744 | +761.1% | 0.00% | – |
| Q1 2021 | $240,000 | -54.1% | 9,609 | -49.9% | 0.00% | – |
| Q4 2020 | $523,000 | – | 19,177 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 895,821 | $8,008,640 | 3.99% |
| Deep Track Capital, LP | 7,370,000 | $65,887,800 | 2.54% |
| VR Adviser, LLC | 2,623,677 | $23,455,672 | 2.47% |
| Sio Capital Management, LLC | 884,770 | $7,909,844 | 2.45% |
| Kynam Capital Management, LP | 957,502 | $8,560,068 | 1.40% |
| MPM BioImpact LLC | 552,846 | $4,942,443 | 1.32% |
| ARMISTICE CAPITAL, LLC | 7,500,000 | $67,050,000 | 1.03% |
| Parkman Healthcare Partners LLC | 577,494 | $5,162,796 | 0.95% |
| Tri Locum Partners LP | 251,702 | $2,250,216 | 0.72% |
| Cheyne Capital Management (UK) LLP | 26,200 | $234,228 | 0.68% |